Activated T lymphocytes are essential drivers of pathological remodeling in ischemic heart failure

Circulation: Heart Failure

Volumn 10, Issue 3, 2017, Pages

  Bansal, Shyam S ^a,b   Ismahil, Mohamed Ameen ^a   Goel, Mehak ^a   Patel, Bindiya ^a   Hamid, Tariq ^a   Rokosh, Gregg ^c   Prabhu, Sumanth D ^a,b  

^a University of Alabama at Birmingham   (United States)

^b BIRMINGHAM VA MEDICAL CENTER   (United States)

^c NONE

Author keywords

adaptive immunity; adoptive transfer; heart failure; inflammation; T lymphocytes

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CYTOKINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; CYTOKINE PRODUCTION; ECHOCARDIOGRAPHY; FLOW CYTOMETRY; GENE EXPRESSION; HEART DILATATION; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HISTOLOGY; IMMUNOCOMPETENT CELL; ISCHEMIC HEART DISEASE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; T CELL DEPLETION; T LYMPHOCYTE; TH1 TH2 BALANCE; ADOPTIVE TRANSFER; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; CELL PROLIFERATION; DISEASE MODEL; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART VENTRICLE REMODELING; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPH NODE; LYMPHOCYTE ACTIVATION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; SPLEEN; T LYMPHOCYTE SUBPOPULATION; TIME FACTOR; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; HEART FAILURE; IMMUNOLOGIC MEMORY; LYMPH NODES; LYMPHOCYTE ACTIVATION; MALE; MICE, INBRED C57BL; MYOCARDIAL ISCHEMIA; MYOCARDIUM; PHENOTYPE; SPLEEN; T-LYMPHOCYTE SUBSETS; TIME FACTORS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 85018174400     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.116.003688     Document Type: Article

References (49)

1. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988-998.
2. Prabhu SD, Chandrasekar B, Murray DR, Freeman GL. Betaadrenergic blockade in developing heart failure: effects on myocardial inflammatory cytokines, nitric oxide, and remodeling. Circulation. 2000;101:2103-2109.
3. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003;107:3133-3140. doi: 10.1161/01.CIR.0000077913.60364.D2.
4. Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116:1254-1268. doi: 10.1161/CIRCRESAHA.116.302317.
5. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, Djian J, Drexler H, Feldman A, Kober L, Krum H, Liu P, Nieminen M, Tavazzi L, van Veldhuisen DJ, Waldenstrom A, Warren M, Westheim A, Zannad F, Fleming T. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004;109:1594-1602. doi: 10.1161/01.CIR.0000124490.27666.B2.
6. Ismahil MA, Hamid T, Bansal SS, Patel B, Kingery JR, Prabhu SD. Remodeling of the mononuclear phagocyte network underlies chronic inflammation and disease progression in heart failure: critical importance of the cardiosplenic axis. Circ Res. 2014;114:266-282. doi: 10.1161/CIRCRESAHA.113.301720.
7. Kushwah R, Hu J. Complexity of dendritic cell subsets and their function in the host immune system. Immunology. 2011;133:409-419. doi: 10.1111/j.1365-2567.2011.03457.x.
8. Hofmann U, Beyersdorf N, Weirather J, Podolskaya A, Bauersachs J, Ertl G, Kerkau T, Frantz S. Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice. Circulation. 2012;125:1652-1663. doi: 10.1161/CIRCULATIONAHA.111.044164.
9. Weirather J, Hofmann UD, Beyersdorf N, Ramos GC, Vogel B, Frey A, Ertl G, Kerkau T, Frantz S. Foxp3+ CD4+ T cells improve healing after myocardial infarction by modulating monocyte/macrophage differentiation. Circ Res. 2014;115:55-67. doi: 10.1161/CIRCRESAHA.115.303895.
10. Sobirin MA, Kinugawa S, Takahashi M, Fukushima A, Homma T, Ono T, Hirabayashi K, Suga T, Azalia P, Takada S, Taniguchi M, Nakayama T, Ishimori N, Iwabuchi K, Tsutsui H. Activation of natural killer T cells ameliorates postinfarct cardiac remodeling and failure in mice. Circ Res. 2012;111:1037-1047. doi: 10.1161/CIRCRESAHA.112.270132.
11. Stabile E, Burnett MS, Watkins C, Kinnaird T, Bachis A, la Sala A, Miller JM, Shou M, Epstein SE, Fuchs S. Impaired arteriogenic response to acute hindlimb ischemia in CD4-knockout mice. Circulation. 2003;108:205-210. doi: 10.1161/01.CIR.0000079225.50817.71.
12. Laroumanie F, Douin-Echinard V, Pozzo J, Lairez O, Tortosa F, Vinel C, Delage C, Calise D, Dutaur M, Parini A, Pizzinat N. CD4+ T cells promote the transition from hypertrophy to heart failure during chronic pressure overload. Circulation. 2014;129:2111-2124. doi: 10.1161/CIRCULATIONAHA.113.007101.
13. Nevers T, Salvador AM, Grodecki-Pena A, Knapp A, Velázquez F, Aronovitz M, Kapur NK, Karas RH, Blanton RM, Alcaide P. Left ventricular t-cell recruitment contributes to the pathogenesis of heart failure. Circ Heart Fail. 2015;8:776-787. doi: 10.1161/CIRCHEARTFAILURE.115.002225.
14. Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, Anand I, Maggioni A, Burton P, Sullivan MD, Pitt B, Poole-Wilson PA, Mann DL, Packer M. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113:1424-1433. doi: 10.1161/CIRCULATIONAHA.105.584102.
15. Dong C. Helper T-cell heterogeneity: a complex developmental issue in the immune system. Cell Mol Immunol. 2010;7:163. doi: 10.1038/cmi.2010.23.
16. Geginat J, Paroni M, Maglie S, Alfen JS, Kastirr I, Gruarin P, De Simone M, Pagani M, Abrignani S. Plasticity of human CD4 T cell subsets. Front Immunol. 2014;5:630. doi: 10.3389/fimmu.2014.00630.
17. Chen Q, Ghilardi N, Wang H, Baker T, Xie MH, Gurney A, Grewal IS, de Sauvage FJ. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature. 2000;407:916-920. doi: 10.1038/35038103.
18. Paul WE, Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol. 2010;10:225-235. doi: 10.1038/nri2735.
19. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485-517. doi: 10.1146/annurev.immunol. 021908.132710.
20. Schmetterer KG, Neunkirchner A, Pickl WF. Naturally occurring regulatory T cells: markers, mechanisms, and manipulation. FASEB J. 2012;26:2253-2276. doi: 10.1096/fj.11-193672.
21. Hamid T, Gu Y, Ortines RV, Bhattacharya C, Wang G, Xuan YT, Prabhu SD. Divergent tumor necrosis factor receptor-related remodeling responses in heart failure: role of nuclear factor-kappaB and inflammatory activation. Circulation. 2009;119:1386-1397. doi: 10.1161/CIRCULATIONAHA.108.802918.
22. Hamid T, Guo SZ, Kingery JR, Xiang X, Dawn B, Prabhu SD. Cardiomyocyte NF-?B p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res. 2011;89:129-138. doi: 10.1093/cvr/cvq274.
23. Wang G, Hamid T, Keith RJ, Zhou G, Partridge CR, Xiang X, Kingery JR, Lewis RK, Li Q, Rokosh DG, Ford R, Spinale FG, Riggs DW, Srivastava S, Bhatnagar A, Bolli R, Prabhu SD. Cardioprotective and antiapoptotic effects of heme oxygenase-1 in the failing heart. Circulation. 2010;121:1912-1925. doi: 10.1161/CIRCULATIONAHA.109.905471.
24. Wysoczynski M, Solanki M, Borkowska S, van Hoose P, Brittian KR, Prabhu SD, Ratajczak MZ, Rokosh G. Complement component 3 is necessary to preserve myocardium and myocardial function in chronic myocardial infarction. Stem Cells. 2014;32:2502-2515. doi: 10.1002/stem.1743.
25. Baaten BJ, Tinoco R, Chen AT, Bradley LM. Regulation of antigen-experienced T cells: lessons from the quintessential memory marker CD44. Front Immunol. 2012;3:23. doi: 10.3389/fimmu.2012.00023.
26. Dutton RW, Bradley LM, Swain SL. T cell memory. Annu Rev Immunol. 1998;16:201-223. doi: 10.1146/annurev.immunol.16.1.201.
27. Sallusto F, Lenig D, Förster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712. doi: 10.1038/44385.
28. Raines EW. Antigen-independent targeting of long-lived CD4+ cytolytic T effector cells to lesions of atherosclerosis. Circ Res. 2006;98:434-436. doi: 10.1161/01.RES.0000214353.38360.a2.
29. Smeltz RB, Chen J, Hu-Li J, Shevach EM. Regulation of interleukin (IL)-18 receptor alpha chain expression on CD4(+) T cells during T helper (Th)1/Th2 differentiation. Critical downregulatory role of IL-4. J Exp Med. 2001;194:143-153.
30. Liao W, Lin JX, Wang L, Li P, Leonard WJ. Modulation of cytokine receptors by IL-2 broadly regulates differentiation into helper T cell lineages. Nat Immunol. 2011;12:551-559. doi: 10.1038/ni.2030.
31. O'Garra A, Vieira PL, Vieira P, Goldfeld AE. IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage. J Clin Invest. 2004;114:1372-1378. doi: 10.1172/JCI23215.
32. Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond). 2011;8:22. doi: 10.1186/1476-9255-8-22.
33. Au-Yeung BB, Fowell DJ. A key role for Itk in both IFN gamma and IL-4 production by NKT cells. J Immunol. 2007;179:111-119.
34. Fuse K, Kodama M, Ito M, Okura Y, Kato K, Hanawa H, Aoki S, Aizawa Y. Polarity of helper T cell subsets represents disease nature and clinical course of experimental autoimmune myocarditis in rats. Clin Exp Immunol. 2003;134:403-408.
35. O'Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity. 2008;28:477-487. doi: 10.1016/j. immuni.2008.03.002.
36. Hilgendorf I, Gerhardt LM, Tan TC, Winter C, Holderried TA, Chousterman BG, Iwamoto Y, Liao R, Zirlik A, Scherer-Crosbie M, Hedrick CC, Libby P, Nahrendorf M, Weissleder R, Swirski FK. Ly-6Chigh monocytes depend on Nr4a1 to balance both inflammatory and reparative phases in the infarcted myocardium. Circ Res. 2014;114:1611-1622. doi: 10.1161/CIRCRESAHA.114.303204.
37. Ismahil MA, Prabhu SD. Cardiac immune cell remodeling after myocardial infarction. J Mol Cell Cardiol. 2013;62:142-143. doi: 10.1016/j. yjmcc.2013.05.017.
38. Leuschner F, Rauch PJ, Ueno T, Gorbatov R, Marinelli B, Lee WW, Dutta P, Wei Y, Robbins C, Iwamoto Y, Sena B, Chudnovskiy A, Panizzi P, Keliher E, Higgins JM, Libby P, Moskowitz MA, Pittet MJ, Swirski FK, Weissleder R, Nahrendorf M. Rapid monocyte kinetics in acute myocardial infarction are sustained by extramedullary monocytopoiesis. J Exp Med. 2012;209:123-137. doi: 10.1084/jem.20111009.
39. Prabhu SD, Frangogiannis NG. The biological basis for cardiac repair after myocardial infarction: from inflammation to fibrosis. Circ Res. 2016;119:91-112. doi: 10.1161/CIRCRESAHA.116.303577.
40. Yan X, Anzai A, Katsumata Y, Matsuhashi T, Ito K, Endo J, Yamamoto T, Takeshima A, Shinmura K, Shen W, Fukuda K, Sano M. Temporal dynamics of cardiac immune cell accumulation following acute myocardial infarction. J Mol Cell Cardiol. 2013;62:24-35. doi: 10.1016/j. yjmcc.2013.04.023.
41. Anzai A, Anzai T, Nagai S, Maekawa Y, Naito K, Kaneko H, Sugano Y, Takahashi T, Abe H, Mochizuki S, Sano M, Yoshikawa T, Okada Y, Koyasu S, Ogawa S, Fukuda K. Regulatory role of dendritic cells in postinfarction healing and left ventricular remodeling. Circulation. 2012;125:1234-1245. doi: 10.1161/CIRCULATIONAHA. 111.052126.
42. Postlethwaite AE, Holness MA, Katai H, Raghow R. Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin J Clin Invest. 1992;90:1479-1485. doi: 10.1172/JCI116015.
43. Roselló-Lletí E, Rivera M, Bertomeu V, Cortés R, Jordán A, González-Molina A. [Interleukin-4 and cardiac fibrosis in patients with heart failure]. Rev Esp Cardiol. 2007;60:777-780.
44. Cieslik KA, Taffet GE, Carlson S, Hermosillo J, Trial J, Entman ML. Immune-inflammatory dysregulation modulates the incidence of progressive fibrosis and diastolic stiffness in the aging heart. J Mol Cell Cardiol. 2011;50:248-256. doi: 10.1016/j.yjmcc.2010.10.019.
45. Tang Q, Bluestone JA. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol. 2008;9:239-244. doi: 10.1038/ni1572.
46. Maisel AS, Knowlton KU, Fowler P, Rearden A, Ziegler MG, Motulsky HJ, Insel PA, Michel MC. Adrenergic control of circulating lymphocyte subpopulations. Effects of congestive heart failure, dynamic exercise, and terbutaline treatment. J Clin Invest. 1990;85:462-467. doi: 10.1172/JCI114460.
47. Satoh S, Oyama J, Suematsu N, Kadokami T, Shimoyama N, Okutsu M, Inoue T, Sugano M, Makino N. Increased productivity of tumor necrosis factor-alpha in helper T cells in patients with systolic heart failure. Int J Cardiol. 2006;111:405-412. doi: 10.1016/j.ijcard.2005.08.021.
48. Mebius RE, Kraal G. Structure and function of the spleen. Nat Rev Immunol. 2005;5:606-616. doi: 10.1038/nri1669.
49. von Andrian UH, Mempel TR. Homing and cellular traffic in lymph nodes. Nat Rev Immunol. 2003;3:867-878. doi: 10.1038/nri1222.